Fax: (713) 563-2331
Marginal zone lymphomas†
Factors that affect the final outcome
Article first published online: 19 AUG 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 18, pages 4291–4298, 15 September 2010
How to Cite
Mazloom, A., Medeiros, L. J., McLaughlin, P. W., Reed, V., Cabanillas, F. F., Fayad, L. E., Pro, B., Gonzalez, G., Iyengar, P., Urbauer, D. L. and Dabaja, B. S. (2010), Marginal zone lymphomas. Cancer, 116: 4291–4298. doi: 10.1002/cncr.25325
Presented in part at the American Society of Hematology Annual Meeting, San Francisco, California, December 6-9, 2008.
- Issue published online: 3 SEP 2010
- Article first published online: 19 AUG 2010
- Manuscript Accepted: 23 FEB 2010
- Manuscript Revised: 2 FEB 2010
- Manuscript Received: 9 DEC 2009
- marginal zone lymphoma;
- mucosa-associated lymphoid tissue;
- prognostic factors;
A retrospective review and analysis of 275 patients with marginal zone lymphoma (MZL) was performed to determine prognostic factors. An effort was also made to establish a specific prognostic score for patients with extranodal MZL.
Patients were divided into 3 groups according to the type of MZL: extranodal, nodal, and splenic. Factors analyzed included age; gender; presence of B symptoms; Zubrod performance score; clinical stage; serum β2-microglobulin, lactate dehydrogenase, albumin, and hemoglobin levels; and presence of autoimmune disorder.
The 5-year overall survival rates of patients with extranodal, nodal, and splenic MZL were 87%, 89%, and 93%, respectively (P = .95). On multivariate analysis, splenic MZL patients had the best prognosis (hazard ratio, 0.18; P = .018). An elevated serum β2-microglobulin level (P = .010), B symptoms (P = .021), and male gender (P = .036) were found to be correlated with decreased recurrence-free survival (RFS) on multivariate analysis. Using these 3 variables, a 3-tier prognostic scoring system was created for patients with extranodal MZL: low-risk with no adverse factors, intermediate-risk with 1 adverse factor, and high-risk with ≥2 adverse factors. The 5-year RFS rates for the low-risk, intermediate-risk, and high-risk groups were 80%, 71%, and 44%, respectively (P = .01).
Patients with extranodal and nodal MZL have a similar prognosis, whereas patients with splenic MZL have a better prognosis despite the increased prevalence of negative prognostic indicators. With the use of 3 readily available factors, a prognostic scoring system was identified for patients with extranodal MZL. Cancer 2010. © 2010 American Cancer Society.